Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

OPDIVO

×

Overview

What is OPDIVO?

Nivolumab is a human monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Nivolumab is an IgG4 kappa immunoglobulin that has a calculated molecular mass of 146 kDa. It is expressed in a recombinant Chinese Hamster Ovary (CHO) cell line.

OPDIVO is a sterile, preservative-free, non-pyrogenic, clear to opalescent, colorless to pale-yellow liquid that may contain light (few) particles. OPDIVO injection for intravenous infusion is supplied in single-dose vials. Each mL of OPDIVO solution contains nivolumab 10 mg, mannitol (30 mg), pentetic acid (0.008 mg), polysorbate 80 (0.2 mg), sodium chloride (2.92 mg), sodium citrate dihydrate (5.88 mg), and Water for Injection, USP. May contain hydrochloric acid and/or sodium hydroxide to adjust pH to 6.



What does OPDIVO look like?



What are the available doses of OPDIVO?

Injection: 40 mg/4 mL, 100 mg/10 mL, and 240 mg/24 mL solution in a single-dose vial.

What should I talk to my health care provider before I take OPDIVO?

Lactation: Discontinue breastfeeding.

How should I use OPDIVO?

OPDIVO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of:

Single Agent

The recommended dose of OPDIVO as a single agent is either:

administered as an intravenous infusion over 30 minutes until disease progression or unacceptable toxicity.

With Ipilimumab

The recommended dose of OPDIVO is 1 mg/kg administered as an intravenous infusion over 30 minutes, followed by ipilimumab 3 mg/kg administered as an intravenous infusion over 90 minutes on the same day, every 3 weeks for a maximum of 4 doses or until unacceptable toxicity, whichever occurs earlier. After completing 4 doses of the combination, administer OPDIVO as a single agent, either:

administered as an intravenous infusion over 30 minutes until disease progression or unacceptable toxicity. Review the Full Prescribing Information for ipilimumab for additional information prior to initiation.


What interacts with OPDIVO?

Sorry No Records found


What are the warnings of OPDIVO?

Sorry No Records found


What are the precautions of OPDIVO?

Sorry No Records found


What are the side effects of OPDIVO?

Sorry No records found


What should I look out for while using OPDIVO?

None.


What might happen if I take too much OPDIVO?

There is no information on overdosage with OPDIVO.


How should I store and handle OPDIVO?

OPDIVO (nivolumab) Injection is available as follows:Store OPDIVO under refrigeration at 2°C to 8°C (36°F to 46°F). Protect OPDIVO from light by storing in the original package until time of use. Do not freeze or shake.OPDIVO (nivolumab) Injection is available as follows:Store OPDIVO under refrigeration at 2°C to 8°C (36°F to 46°F). Protect OPDIVO from light by storing in the original package until time of use. Do not freeze or shake.